Jeff Dykan - 09 Jul 2026 Form 4 Insider Report for REGENTIS BIOMATERIALS LTD. (RGNT)

Reporting relationship: Director
Issuer ticker: RGNT
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jul 2026, 17:06:00 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeff Dykan

Key filing fact

Jeff Dykan filed Form 4 for REGENTIS BIOMATERIALS LTD. (RGNT) on 13 Jul 2026.

Key facts

This page summarizes Jeff Dykan's Form 4 filing for REGENTIS BIOMATERIALS LTD. (RGNT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Jul 2026, 17:06.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001661229 Primary reporting owner

Dykan Jeff

Relationship: Director
Address: C/O REGENTIS BIOMATERIALS LTD., 60 MEDINAT HAYHEHUDIM, HERZLIYA, ISRAEL
Signature: /s/ Jeff Dykan
Signature date: 13 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGNT transaction Derivative

Warrants to purchase ordinary shares

Award

Transaction value
Shares: +12,500
Change %
Price: $0.000000^*
Shares after: 12,500
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 12,500
Exercise price: $0.003000
Footnotes: F1, F2

RGNT transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +24,826
Change %
Price: $0.000000^*
Shares after: 24,826
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 24,826
Exercise price: $2.16
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

Footnote F2

The warrants are currently exercisable and have a three year term.

Footnote F3

This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

Footnote F4

This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029.

Footnote F5

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.